This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Investigating the Phase 1 clinical trial data for VK2735, an oral GLP-1 and GIP agonist being developed by Viking Therapeutics for the treatment of metabolic disorders such as obesity.

Ticker(s): VKTX

Who's the expert?

Institution: Diabetes and Metabolism Specialists 

  • Endocrinologist at Diabetes and Metabolism Specialists in San Antonio, Texas
  • Diabetes and Metabolism physician who manages over 500 type 1 diabetes patients, 300 of which are on insulin pumps
  • Research interest in inititation, titration, and switching of basal insulins 

Interview Goal
to discuss the current standard of care and the potential of VK2735, an oral dual GLP-1 and GIP agonist being developed by Viking Therapeutics for the treatment of metabolic disorders such as obesity.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.